Distinctive Effects of Fullerene C60 and Fullerenol C60(OH)24 Nanoparticles on Histological, Molecular and Behavioral Hallmarks of Alzheimer’s Disease in APPswe/PS1E9 Mice
Antioxidants · 08.07.2025 · 14 (7) · 834
DOI: 10.3390/antiox14070834 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antioxidants, online erschienen am 08.07.2025. Verfasst von Sholpan Askarova und 14 weiteren Autor:innen. Beteiligte Einrichtung: Center for Life Sciences, National Laboratory Astana, Nazarbayev University, Astana 010000, Kazakhstan. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Higher Education and Science of the Republic of Kazakhstan, EU Marie-Curie Skłodowska" PhytoApp", Ministry of Science and Higher Education of RF.
Themen: Demenz
Abstract (Originalsprache)
Fullerenes and fullerenols exhibit antioxidant and anti-inflammatory properties, making them promising candidates for Alzheimer’s disease (AD) therapy. Unlike conventional anti-inflammatory drugs, these compounds have multitargeted effects, including their ability to inhibit amyloid fibril formation. However, few studies have explored their efficacy in high-validity AD models. Female APPswe/PS1E9 (APP/PS1) mice and their wild-type (WT) littermates were orally administered with fullerene C60 (0.1 mg/kg/day) or fullerenol C60(OH)24 (0.15 mg/kg/day) for 10 months starting at 2 months of age. Behavioral assessments were performed at 12 months of age. Amyloid plaque density and size were analyzed in the brain regions using Congo red staining. The expression of genes related to inflammation and plasticity was examined, and an in vitro assay was used to test the toxicity of fullerenol and its effect on amyloid β peptide 42 (Aβ42)-induced reactive oxygen species (ROS) production. Fullerenol reduced the maximum plaque size in the cortex and hippocampus, decreased the small plaque density in the hippocampus and thalamus, and prevented an increase in glial fibrillary acidic protein (GFAP) positive cell density in the mutants. Both treatments improved cognitive and emotional behaviors and reduced Il1β and increased Sirt1 expression. In vitro, fullerenol was non-toxic across a range of concentrations and reduced Aβ42-induced ROS production in brain endothelial cells and astrocytes. Long-term administration of fullerene or fullerenol improved behavioral and molecular markers of AD in APP/PS1 mice, with fullerenol showing additional benefits in reducing amyloid burden.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center for Life Sciences, National Laboratory Astana, Nazarbayev University, Astana 010000, Kazakhstan.
- Institute of General Pathology and Pathophysiology, Moscow 125315, Russia.
- Department of General Biology and Genomics, Faculty of Natural Sciences, L.N. Gumilyov Eurasian National University, Astana 010000, Kazakhstan.
- Institute of Physiologically Active Compounds at Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences, Chernogolovka 119071, Russia.
- Neuroplast BV, 6222 NK Maastricht, The Netherlands.
- Research and Education Resource Center, Peoples Friendship University of Russia, Moscow 117198, Russia.
ORCID-Profile: Sholpan Askarova, Aliya Kassenova, Kirill Chaprov, Evgeniy Svirin, Andrey Tsoy, Johannes de Munter, Aleksandr Litavrin, Nurbol Appazov
Förderung
- Ministry of Higher Education and Science of the Republic of Kazakhstan
- EU Marie-Curie Skłodowska" PhytoApp"
- Ministry of Science and Higher Education of RF
- State Task of the Laboratory of Genetic Technologies and Genome Editing for Biomedicine and Animal Health
- PhytoApp EU framework
- European Union’s H2020-MSCA-RISE-2020 research and innovation program
- FFSG-2024-0020
Zitieren
APA
Askarova, S., Sitdikova, K., Kassenova, A., Chaprov, K., Svirin, E., Tsoy, A., de Munter, J., Gorlova, A., Litavrin, A., Deikin, A., Nedorubov, A., Appazov, N., Kalueff, A., Chernopiatko, A., & Strekalova, T. (2025). Distinctive Effects of Fullerene C60 and Fullerenol C60(OH)24 Nanoparticles on Histological, Molecular and Behavioral Hallmarks of Alzheimer’s Disease in APPswe/PS1E9 Mice. Antioxidants, 14(7), 834. https://doi.org/10.3390/antiox14070834
Vancouver
Askarova S, Sitdikova K, Kassenova A, Chaprov K, Svirin E, Tsoy A, et al. Distinctive Effects of Fullerene C60 and Fullerenol C60(OH)24 Nanoparticles on Histological, Molecular and Behavioral Hallmarks of Alzheimer’s Disease in APPswe/PS1E9 Mice. Antioxidants. 2025;14(7):834. doi:10.3390/antiox14070834
BibTeX
@article{Askarova2025,
author = {Askarova, Sholpan and Sitdikova, Kseniia and Kassenova, Aliya and Chaprov, Kirill and Svirin, Evgeniy and Tsoy, Andrey and de Munter, Johannes and Gorlova, Anna and Litavrin, Aleksandr and Deikin, Aleksei and Nedorubov, Andrey and Appazov, Nurbol and Kalueff, Allan and Chernopiatko, Anton and Strekalova, Tatyana},
title = {Distinctive Effects of Fullerene C60 and Fullerenol C60(OH)24 Nanoparticles on Histological, Molecular and Behavioral Hallmarks of Alzheimer’s Disease in APPswe/PS1E9 Mice},
journal = {Antioxidants},
year = {2025},
volume = {14},
number = {7},
pages = {834},
doi = {10.3390/antiox14070834}
}
EUVIMED